Richardson pg et al. blood 2014 123:1826–32
Webb26 feb. 2015 · The incidence rate of grade 3 and 4 AEs was 45 (90%), including hematologic AEs, and 32 (64%) experienced a serious adverse event (SAE). Ten patients … Webb7 sep. 2024 · In addition to the above criteria, if a plasmacytoma was present at baseline, ≥50% reduction in the size of soft tissue plasmacytomas was also required. CR required …
Richardson pg et al. blood 2014 123:1826–32
Did you know?
Webb15 nov. 2007 · Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. … Webb3 mars 2024 · Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826–32. Article CAS PubMed PubMed Central Google Scholar
WebbRichardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832. 58. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. Webb13 maj 2024 · Richardson PG ; Siegel DS ; Vij R ; et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123: 1826-1832. Crossref; PubMed; Scopus (307) ... (32%) III: 47 (17%) 50 (18%) Cytogenetic profile by FISH: Standard risk: 137 (49%) 132 …
Webb7 okt. 2024 · Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123: 1826 – 1832. , , [Web of Science ®], [Google Scholar] Webb7 sep. 2024 · Details of the OPTIMISMM trial have been previously reported by Richardson et al ... Richardson PG, Crowley J, et al. Risk of progression and survival in multiple ...
Webb14 mars 2013 · [email protected] PMID: 23243282 PMCID: PMC4123324 DOI: 10.1182/blood-2012-08-450742 Abstract This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and …
Webb28 juni 2024 · Multiple myeloma and MGUS fall on a continuum, with 20% of patients with MGUS progressing to multiple myeloma within 10 years. In most patients with a monoclonal plasma cell disorder, whether... cumberland city tn 37050Webb6 jan. 2016 · Richardson PG Siegel DS Vij R et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123: 1826-1832 View in Article Scopus (306) PubMed Crossref Google Scholar 9. Lonial S Dimopoulos M Palumbo A et al. east princetonWebb6 maj 2024 · Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a ... east primary sutherlin oregonWebb1 nov. 2015 · The overall response rate (ORR) was 45% among all patients and 53% among those who received the MTD. Responses in the MTD cohort were durable, with a median … east price hill houses for saleWebb25 aug. 2014 · Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a... cumberland city tn motelsWebb23 feb. 2024 · This open-label, multicenter phase I/II study was designed to assess the safety, tolerability, and activity of weekly oral ixazomib combined with pomalidomide and dexamethasone in patients with... east princeton place southeast of auroraWebb24 juli 2024 · Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and … east print gmbh